The aim of this study was to determine whether T cells co-expressing both a human anti-CD19-specific single-chain variable fragment (scFv) CAR (CD19 CAR) and tTRII-I7R (CD19 CAR-tTRII-I7R-T cells) showed improved anti-tumor efficacy and inhibition of recurrence in a CD19+ B cell lymphoma mouse model. Here, CD19 is linked to neoplasm.